Name | Number of supported studies | Average coverage | |
---|---|---|---|
plasmacytoid dendritic cell | 8 studies | 23% ± 6% | |
endothelial cell | 7 studies | 26% ± 14% | |
astrocyte | 7 studies | 26% ± 8% | |
oligodendrocyte precursor cell | 6 studies | 20% ± 5% | |
adipocyte | 6 studies | 22% ± 5% | |
oligodendrocyte | 5 studies | 24% ± 6% | |
epithelial cell | 4 studies | 31% ± 18% | |
GABAergic neuron | 4 studies | 35% ± 4% | |
glutamatergic neuron | 4 studies | 39% ± 10% | |
microglial cell | 3 studies | 20% ± 2% | |
interneuron | 3 studies | 33% ± 6% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 6 studies | 30% ± 10% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
pancreas | 99% | 295.81 | 325 / 328 | 94% | 3.21 | 167 / 178 |
breast | 98% | 336.25 | 448 / 459 | 89% | 3.54 | 996 / 1118 |
brain | 89% | 153.80 | 2364 / 2642 | 97% | 4.01 | 684 / 705 |
intestine | 88% | 563.35 | 854 / 966 | 96% | 8.00 | 507 / 527 |
prostate | 87% | 152.80 | 214 / 245 | 97% | 6.11 | 486 / 502 |
stomach | 90% | 143.79 | 324 / 359 | 94% | 6.56 | 268 / 286 |
kidney | 94% | 221.28 | 84 / 89 | 85% | 2.69 | 769 / 901 |
uterus | 75% | 119.76 | 128 / 170 | 85% | 5.17 | 391 / 459 |
lung | 76% | 123.17 | 437 / 578 | 82% | 2.92 | 943 / 1155 |
ovary | 71% | 102.09 | 128 / 180 | 86% | 2.60 | 369 / 430 |
bladder | 71% | 89.24 | 15 / 21 | 82% | 3.99 | 411 / 504 |
esophagus | 71% | 118.14 | 1024 / 1445 | 81% | 3.77 | 148 / 183 |
skin | 70% | 100.29 | 1259 / 1809 | 77% | 2.37 | 362 / 472 |
thymus | 83% | 140.49 | 545 / 653 | 56% | 1.54 | 336 / 605 |
liver | 70% | 149.73 | 159 / 226 | 66% | 2.63 | 268 / 406 |
adrenal gland | 60% | 68.98 | 155 / 258 | 51% | 1.42 | 117 / 230 |
muscle | 100% | 1816.97 | 803 / 803 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 1.65 | 1 / 1 |
spleen | 100% | 381.12 | 240 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 99% | 1504.12 | 922 / 929 | 0% | 0 | 0 / 0 |
adipose | 96% | 259.65 | 1154 / 1204 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 78% | 2.19 | 35 / 45 |
lymph node | 0% | 0 | 0 / 0 | 76% | 4.61 | 22 / 29 |
blood vessel | 63% | 107.72 | 845 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 45% | 0.72 | 36 / 80 |
heart | 42% | 49.52 | 365 / 861 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0002931 | Biological process | response to ischemia |
GO_0051770 | Biological process | positive regulation of nitric-oxide synthase biosynthetic process |
GO_0000165 | Biological process | MAPK cascade |
GO_0001649 | Biological process | osteoblast differentiation |
GO_0007165 | Biological process | signal transduction |
GO_0001934 | Biological process | positive regulation of protein phosphorylation |
GO_0043410 | Biological process | positive regulation of MAPK cascade |
GO_0060048 | Biological process | cardiac muscle contraction |
GO_0072709 | Biological process | cellular response to sorbitol |
GO_0051403 | Biological process | stress-activated MAPK cascade |
GO_0022602 | Biological process | ovulation cycle process |
GO_1901796 | Biological process | regulation of signal transduction by p53 class mediator |
GO_0032308 | Biological process | positive regulation of prostaglandin secretion |
GO_0006915 | Biological process | apoptotic process |
GO_0031098 | Biological process | stress-activated protein kinase signaling cascade |
GO_0090398 | Biological process | cellular senescence |
GO_0009410 | Biological process | response to xenobiotic stimulus |
GO_0060348 | Biological process | bone development |
GO_0038066 | Biological process | p38MAPK cascade |
GO_0043065 | Biological process | positive regulation of apoptotic process |
GO_0042770 | Biological process | signal transduction in response to DNA damage |
GO_0051726 | Biological process | regulation of cell cycle |
GO_0035872 | Biological process | nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway |
GO_0120163 | Biological process | negative regulation of cold-induced thermogenesis |
GO_0005856 | Cellular component | cytoskeleton |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0106310 | Molecular function | protein serine kinase activity |
GO_0004713 | Molecular function | protein tyrosine kinase activity |
GO_0004708 | Molecular function | MAP kinase kinase activity |
GO_0019901 | Molecular function | protein kinase binding |
GO_0004674 | Molecular function | protein serine/threonine kinase activity |
GO_0005524 | Molecular function | ATP binding |
GO_0005515 | Molecular function | protein binding |
Gene name | MAP2K6 |
Protein name | Dual specificity mitogen-activated protein kinase kinase 6 (MAP kinase kinase 6) (MAPKK 6) (EC 2.7.12.2) (MAPK/ERK kinase 6) (MEK 6) (Stress-activated protein kinase kinase 3) (SAPK kinase 3) (SAPKK-3) (SAPKK3) Mitogen-activated protein kinase kinase 6 mitogen-activated protein kinase kinase (EC 2.7.12.2) |
Synonyms | MEK6 MKK6 hCG_28772 SKK3 PRKMK6 |
Description | FUNCTION: Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. With MAP3K3/MKK3, catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in the MAP kinases p38 MAPK11, MAPK12, MAPK13 and MAPK14 and plays an important role in the regulation of cellular responses to cytokines and all kinds of stresses. Especially, MAP2K3/MKK3 and MAP2K6/MKK6 are both essential for the activation of MAPK11 and MAPK13 induced by environmental stress, whereas MAP2K6/MKK6 is the major MAPK11 activator in response to TNF. MAP2K6/MKK6 also phosphorylates and activates PAK6. The p38 MAP kinase signal transduction pathway leads to direct activation of transcription factors. Nuclear targets of p38 MAP kinase include the transcription factors ATF2 and ELK1. Within the p38 MAPK signal transduction pathway, MAP3K6/MKK6 mediates phosphorylation of STAT4 through MAPK14 activation, and is therefore required for STAT4 activation and STAT4-regulated gene expression in response to IL-12 stimulation. The pathway is also crucial for IL-6-induced SOCS3 expression and down-regulation of IL-6-mediated gene induction; and for IFNG-dependent gene transcription. Has a role in osteoclast differentiation through NF-kappa-B transactivation by TNFSF11, and in endochondral ossification and since SOX9 is another likely downstream target of the p38 MAPK pathway. MAP2K6/MKK6 mediates apoptotic cell death in thymocytes. Acts also as a regulator for melanocytes dendricity, through the modulation of Rho family GTPases. . |
Accessions | ENST00000589295.5 P52564 K7ELM6 B5BU16 A0A0A0MRF7 A8K3Y2 ENST00000359094.7 ENST00000588110.5 ENST00000590474.7 [P52564-1] K7EIW3 ENST00000589647.5 [P52564-2] |